glp 1 gip triple agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor Triple GLP-1 / GIP /

Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinsons disease

Neuroprotective Effects of Tirzepatide Recent preclinical studies demonstrate the beneficial effects of tirzepatide on the nervous system [78], particularly in the settings of both Alzheimer's and Parkinson's disease (PD) [79]

Some studies paint an even starker picture, showing four times more retained gastric contents (13.6% versus 2.3%) [1]

Sitagliptin was the first agent introduced (in 2006) with other substances having followed soon after